SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 287 filers reported holding SAGE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $617,400 | +45.9% | 30,000 | +233.3% | 0.00% | 0.0% |
| Q2 2023 | $423,180 | -13.9% | 9,000 | -23.2% | 0.00% | -33.3% |
| Q1 2023 | $491,561 | -85.3% | 11,715 | -86.7% | 0.00% | -85.0% |
| Q4 2022 | $3,350,408 | -13.7% | 87,845 | -11.4% | 0.02% | +25.0% |
| Q3 2022 | $3,881,000 | +817.1% | 99,100 | +1001.1% | 0.02% | +1500.0% |
| Q2 2022 | $423,180 | -20.2% | 9,000 | +22.6% | 0.00% | -50.0% |
| Q4 2019 | $530,000 | -13.1% | 7,341 | +68.9% | 0.00% | -50.0% |
| Q3 2019 | $610,000 | -21.4% | 4,347 | +2.5% | 0.00% | -20.0% |
| Q2 2019 | $776,000 | +9.8% | 4,241 | -4.6% | 0.01% | +25.0% |
| Q1 2019 | $707,000 | +42.3% | 4,447 | -14.3% | 0.00% | +33.3% |
| Q4 2018 | $497,000 | +4.9% | 5,192 | +54.8% | 0.00% | +50.0% |
| Q3 2018 | $474,000 | – | 3,354 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |